{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:39:53Z","timestamp":1785148793923,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.euroneuro.2012.03.004","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T14:52:12Z","timestamp":1334242332000},"page":"825-835","source":"Crossref","is-referenced-by-count":89,"title":["A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder"],"prefix":"10.1016","volume":"22","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Hatim","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Huberlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupe","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.euroneuro.2012.03.004_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/(SICI)1097-0258(19970315)16:5<583::AID-SIM433>3.0.CO;2-Z","article-title":"Power of logrank test and Cox regression model in clinical trials with heterogeneous samples","volume":"16","author":"Akazawa","year":"1997","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2012.03.004_bib2","series-title":"Diagnostic and statistical manual of mental disorders","author":"APA","year":"2000"},{"issue":"12","key":"10.1016\/j.euroneuro.2012.03.004_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.biopsych.2004.09.022","article-title":"Mood state at study entry as predictor of the polarity of relapse in bipolar disorder","volume":"56","author":"Calabrese","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2012.03.004_bib4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1177\/0269881109106900","article-title":"Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis","volume":"24","author":"Cipriani","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2012.03.004_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1034\/j.1600-0447.2002.1e003.x","article-title":"Non-adherence in psychiatric disorders: misbehaviour or clinical feature?","volume":"105","author":"Colom","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"issue":"8","key":"10.1016\/j.euroneuro.2012.03.004_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4088\/JCP.v61n0802","article-title":"Clinical factors associated with treatment noncompliance in euthymic bipolar patients","volume":"61","author":"Colom","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 5","key":"10.1016\/j.euroneuro.2012.03.004_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1399-5618.2005.00248.x","article-title":"Identifying and improving non-adherence in bipolar disorders","volume":"7","author":"Colom","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2012.03.004_bib9","doi-asserted-by":"crossref","unstructured":"De Fruyt, J., Deschepper, E., Audenaert, K., Constant, E., Floris, M., Pitchot, W., Sienaert, P., Souery, D., Claes, S., 2011. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J. Psychopharmacol. [Epub ahead of print] PubMed PMID: 21940761.","DOI":"10.1177\/0269881111408461"},{"key":"10.1016\/j.euroneuro.2012.03.004_bib8","unstructured":"Eli Lilly and Company, 2010. Zyprexa 2.5mg, 5mg, 7.5mg, 10mg, 15mg, and 20mg Coated Tablets. Zyprexa Velotab 5mg, 10mg, 15mg, and 20mg Orodispersible Tablets. Eli Lilly & Co. Ltd., Basingstoke."},{"key":"10.1016\/j.euroneuro.2012.03.004_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-0179-5-3","article-title":"A systematic review of the evidence of the burden of bipolar disorder in Europe","volume":"5","author":"Fajutrao","year":"2009","journal-title":"Clin. Pract. Epidemol. Ment. Health"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.03.004_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00043764-200301000-00007","article-title":"The health and productivity cost burden of the \u2018top 10\u2019 physical and mental health conditions affecting six large U.S. employers in 1999","volume":"45","author":"Goetzel","year":"2003","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.euroneuro.2012.03.004_bib12","series-title":"Manic-depressive illness: bipolar disorders and recurrent depression","author":"Goodwin","year":"2007"},{"issue":"6","key":"10.1016\/j.euroneuro.2012.03.004_bib13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.pnpbp.2007.04.017","article-title":"Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder","volume":"31","author":"Han","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.03.004_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.9.1.9","article-title":"Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness","volume":"9","author":"Keith","year":"2009","journal-title":"Expert Rev. Neurother."},{"issue":"8","key":"10.1016\/j.euroneuro.2012.03.004_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1399-5618.2009.00761.x","article-title":"A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently","volume":"11","author":"Macfadden","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2012.03.004_bib16","unstructured":"Martinez, G., Schreiner, A., 2009. Risperidone Long-Acting Injectable and Olanzapine Pamoate: Review of Short- and Long-Term Safety Data (Abstract #P-28-018). World Congress of Biological Psychiatry."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.03.004_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2012.03.004_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.clinthera.2006.05.014","article-title":"Long-acting risperidone: focus on safety","volume":"28","author":"M\u00f6ller","year":"2006","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.euroneuro.2012.03.004_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1G378","article-title":"Risperidone treatment of bipolar mania","volume":"40","author":"Nguyen","year":"2006","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.03.004_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","article-title":"Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)","volume":"24","author":"Olivares","year":"2009","journal-title":"Eur. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2012.03.004_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.neubiorev.2007.04.003","article-title":"Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena","volume":"31","author":"Post","year":"2007","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.euroneuro.2012.03.004_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","article-title":"Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder","volume":"68","author":"Quiroz","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2012.03.004_bib23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/appi.ps.62.9.1032","article-title":"Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder","volume":"62","author":"Rascati","year":"2011","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.03.004_bib24","first-page":"CD004043","article-title":"Risperidone alone or in combination for acute mania","author":"Rendell","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.euroneuro.2012.03.004_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0006-3223(03)00420-7","article-title":"Social and economic burden of mood disorders","volume":"54","author":"Simon","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.03.004_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine","volume":"163","author":"Tohen","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2012.03.004_bib27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1176\/appi.ajp.162.7.1281","article-title":"Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial","volume":"162","author":"Tohen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2012.03.004_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1034\/j.1399-5618.2001.30504.x","article-title":"Clinical correlates of psychiatric comorbidity in bipolar I patients","volume":"3","author":"Vieta","year":"2001","journal-title":"Bipolar Disord."},{"issue":"10","key":"10.1016\/j.euroneuro.2012.03.004_bib29","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4088\/JCP.v62n1011","article-title":"Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study","volume":"62","author":"Vieta","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.03.004_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15622970701530917","article-title":"A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone","volume":"9","author":"Vieta","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2012.03.004_bib31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1017\/S146114571100040X","article-title":"Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study","volume":"14","author":"Vieta","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2012.03.004_bib32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.09m05284yel","article-title":"A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome","volume":"70","author":"Weiden","year":"2009","journal-title":"J. Clin. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T05:36:24Z","timestamp":1561613784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0924977X12000600"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.03.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}